EUVIMEDEUVIMED entdecken
Crossref

De-escalation trials do not always need to be noninferiority: a case for superiority design de-escalation trials in oncology

Bishal Gyawali iD

JNCI: Journal of the National Cancer Institute · 01.08.2026 · 118 (8) · 1364-1367

DOI: 10.1093/jnci/djaf322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 05.11.2025. Verfasst von Bishal Gyawali. Beteiligte Einrichtung: Department of Oncology, Department of Public Health Sciences and Division of Cancer Care and Epidemiology, Queen's University, Kingston, Ontario, Can…. Hauptthemen laut MEDLINE: Research Design, Neoplasms, Equivalence Trials as Topic, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

De-escalation trials in oncology have received increased attention recently because there is a growing concern that patients with cancer are being overtreated—more patients (than would benefit) are being treated, earlier in the disease course, at a higher dose, for a longer duration, at a higher frequency. Thus, it is important to understand if less treatment allows us to achieve similar outcomes, a strategy referred to as de-escalation of treatment. However, one of the major concerns with such de-escalation strategies is the possibility of compromising treatment efficacy. Although de-escalated treatment with lesser therapeutic burden is a worthwhile goal in itself because it leads to less physical, financial, and time toxicities, de-escalation cannot come at a substantial compromise of treatment efficacy. The commonest way to test whether such de-escalation strategies are safe and do not lead to unacceptable compromise in efficacy is through a noninferiority design trial. Such trials require a larger sample size and, thus, more funding and longer time to be completed. However, de-escalation trials do not necessarily need to be a noninferiority design. In this article, I make a case for using a superiority design to test de-escalation strategies. This will avoid the limitations of noninferiority design and make de-escalation strategies more efficient to test.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignNeoplasmsEquivalence Trials as TopicAntineoplastic AgentsClinical Trials as TopicMedical OncologyHumansTreatment OutcomeSample Size

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Department of Public Health Sciences and Division of Cancer Care and Epidemiology, Queen's University, Kingston, Ontario, Canada.
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

ORCID-Profile: Bishal Gyawali

Zitieren

APA

Gyawali, B. (2026). De-escalation trials do not always need to be noninferiority: a case for superiority design de-escalation trials in oncology. JNCI: Journal of the National Cancer Institute, 118(8), 1364-1367. https://doi.org/10.1093/jnci/djaf322

Vancouver

Gyawali B. De-escalation trials do not always need to be noninferiority: a case for superiority design de-escalation trials in oncology. JNCI: Journal of the National Cancer Institute. 2026;118(8):1364-1367. doi:10.1093/jnci/djaf322

BibTeX
@article{Gyawali2026,
  author = {Gyawali, Bishal},
  title = {De-escalation trials do not always need to be noninferiority: a case for superiority design de-escalation trials in oncology},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  volume = {118},
  number = {8},
  pages = {1364--1367},
  doi = {10.1093/jnci/djaf322}
}
Kostenlos starten →